Quotes 5-day view Delayed Nyse
10/26/2020
10/27/2020
10/28/2020
10/29/2020
10/30/2020
Date
83.92(c)
82.71(c)
80.49(c)
80.67(c)
85.1(c)
Last
7 986 251
6 705 599
11 480 182
8 876 696
18 065 087
Volume
-0.50% -1.44% -2.68% +0.22% +5.49% Change
Sales 2020
45 519 M - -
Net income 2020
-
-
-
Net Debt 2020
74 016 M - -
P/E ratio 2020
21,8x
Yield 2020
5,80%
Sales 2021
53 260 M - -
Net income 2021
16 914 - -
Net Debt 2021
63 003 M - -
P/E ratio 2021
9,58x
Yield 2021
6,04%
Capitalization
142 B 142 B -
EV / Sales 2020
4,75x
EV / Sales 2021
3,86x
Nbr of Employees
47 000
Free-Float
98,5%
AbbVie Inc. specializes in therapeutic drug research and development. Its products are intended for treating rheumatoid arthritis, psoriasis, Crohnâ'Ts disease, thyroid disease, Parkinsonâ'Ts disease, HIV, complications of mucoviscidosis, low testosterone levels, and complications associated with chronic renal disease.
Sales are distributed geographically as follows: the United States (71.9%), Japan (3.7%), Germany...
Notations Surperformance© of AbbVie Inc.
Trading Rating : Investor Rating :
All news about ABBVIE INC.
11:43a GLOBAL MARKETS LIVE : Alphabet, Amazon, Starbucks…10:22a Wall St slumps as tech stocks slide, COVID cases jump RE
09:51a ABBVIE : Correction to AbbVie Earnings ArticleDJ
08:23a ABBVIE : Logs 3Q Sales Growth on Higher Immunology, Oncology ResultsDJ
07:57a ABBVIE : 3Q Earnings SnapshotAQ
07:54a ABBVIE INC. : Results of Operations and Financial Condition, Financial Statement..AQ
10/29 ABBVIE : Allergan, an AbbVie Company, Announces Positive Phase 3 Topline Results..AQ
10/29 ABBVIE : Highlights Innovative Research for People with Rheumatic Diseases with ..AQ
10/29 ABBVIE : to Present New Analyses from Pivotal Phase 3 Studies for RINVOQ™ ..PR
10/28 ABBVIE : Allergan Presbyopia Treatment Hits Main Endpoint in Phase 3 StudiesDJ
10/28 ABBVIE : Allergan, an AbbVie Company, Announces Positive Phase 3 Topline Results..PR
10/28 Molecular Partners jumps after Novartis deal for potential COVID-19 drugs RE
10/28 Molecular Partners jumps after Novartis deal for potential COVID-19 drugs RE
10/27 ABBVIE INC. : quaterly earnings release10/19 ABBVIE : Seeks U.S., European OK of Rinvoq in EczemaDJ
News in other languages on ABBVIE INC.
Bill Gross predicts value outperforms growth, based on rates correlation
Duration :
Auto.
2 months
3 months
6 months
9 months
1 year
2 years
5 years
10 years
Max.
Period :
Day
Week
Technical analysis trends ABBVIE INC.
Short Term Mid-Term Long Term Trends Neutral Bearish Bullish
Income Statement Evolution
Please enable JavaScript in your browser's settings to use dynamic charts.
Mean consensus
BUY
Number of Analysts
20
Average target price
109,25 $
Last Close Price
85,10 $
Spread / Highest target
49,2%
Spread / Average Target
28,4%
Spread / Lowest Target
12,8%
Please enable JavaScript in your browser's settings to use dynamic charts.
Canada
Deutschland
France
Schweiz (DE)
United Kingdom
Report
